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INTRODUCTION : 
Now that routine laboratory testing is automated and is 
frequently part of an annual health check up plans, physicians are 
often faced with the problem of a patient with one abnormal result on 
the measurement of serum Aminotransferases or Alkaline phosphatase 
but no symptoms. Many batteries of screening test now include 
measurement of serum Alanine aminotransferase, Aspartate 
aminotransferase, Alkaline phosphatase and Gamma-glutamyl 
transferase(1). Although these enzymes are present in many tissues 
through out the body, they are most often elevated in patients with 
liver disease and may reflect liver injury. The clinician should be aware 
of non-hepatic diseases that can cause abnormal liver enzymes, such 
as thyroid disorders and occult celiac disease. In those patients in 
which no explanation can be found at the time of the initial evaluation 
for these abnormal liver enzymes, there is a high probability of 
Nonalcoholic Fatty Liver Disease( NAFLD ) due to obesity. 
Several carefully conducted clinical studies, which included liver 
biopsy in all patients, have shown that most asymptomatic subjects 
with persistent liver tests abnormalities in the absence of specific 
biochemical markers or abnormal 
imaging, have Nonalcoholic fatty liver disease( NAFLD )(2,3). 
Nonalcoholic fatty liver disease is the common explanation for 
abnormal liver function test results in blood donors, and it is the cause 
of asymptomatic elevation of Sr. Aminotransferase levels in upto 90% 
of cases once other causes of liver disease are excluded(3). 
Nonalcoholic Fatty liver disease is the most common cause of abnormal 
liver test results among adults in the United states. Obesity, Type 2 
diabetes Mellitus, and dyslipidemia are co-existing conditions 
frequently associated with Nonalcoholic Fatty liver disease. The 
reported prevalence of obesity in several series of patients with NAFLD 
varied between 30 to 100 percent, the prevalence of type 2 diabetes 
varied between 10 and 70 percent, and the prevalence of dyslipidemia 
varied between 20 and 92 percent(4-19). Because Nonalcoholic Fatty 
liver disease is reversible, considerably by lifestyle interventions that 
also affect levels of established risk  factors (such as regular exercise, 
strict glycaemic control and changing dietary habits), there is  
increasing interest in the causative factors and pathogenesis of this 
condition. 
 
SERUM TRANSAMINASES 
The serum transaminases are Aspartate aminotransferase ( AST, 
Aspartate transaminase, Glutamate oxaloacetate transaminase ) and 
Alanine aminotransferase (ALT, Alanine transaminase, Glutamate 
pyruvate transaminase )(20). 
The serum transaminases are a group of enzymes that catalyse 
the interconversions of the aminoacids and alpha-oxoacids by transfer 
of amino groups. 
   CLINICAL SIGNIFICANCE 
Transaminases are widely distributed in the human tissues. Both 
the transaminases are normally present in the human plasma, bile, 
cerebrospinal fluid and saliva, but none is detected in urine unless a 
kidney lesion is present. 
Sr. AST is a mitochondrial enzyme present in large quantities in 
liver, heart, skeletal muscle and kidney and the Sr. AST levels increases 
whenever these tissues are acutely destroyed, presumably from 
damaged cells.(21) 
Sr. ALT is a cytosolic enzyme also present in liver. Although the 
absolute quantity is less than Sr. AST, a greater proportion is present in 
liver compared to heart and skeletal muscle. An increase in Sr. ALT is 
therefore more specific for liver damage than Sr. AST. Hence these two 
enzymes are important markers of liver injury and hence included in 
the liver function tests.(22,1) 
Apart from Sr. AST and Sr. ALT, other components of liver 
function tests are Sr. Bilurubin( direct and indirect ),Sr. Alkaline 
phosphatase,Sr. Gamma glutamate transferase, Sr. Albumin and Sr. 
Globulin. Prothrombin time is also an important marker showing the 
extent and severity of liver damage(1). 
Both these enzymes are elevated in multiple diseased states and 
just not specific for one particular disease. For example, Sr. AST is 
elevated in myocardial infarction(23), other than the diseases of the 
liver. The Sr. Aminotrasferases levels are sensitive indicators of liver 
cell injury and are helpful in recognizing hepatocellular diseases such 
as hepatitis. Both the enzymes Sr. AST and Sr. ALT are released into 
blood in increasing amounts when the liver cell membrane is damaged. 
Necrosis of the liver cells are required for the release of the 
Aminotransferases. Infact there is poor correlation between the extent 
of liver damage and the level of Sr. Aminotransferases. 
CAUSES OF CHRONICALLY ELEVATED 
TRANSAMINASES LEVELS(24) 
HEPATIC CAUSES 
1. Alcohol abuse 
2. Medication ( See Box Below ) 
3. Chronic Hepatitis B and C 
4. Steatosis and Nonalcoholic Fatty Liver Disease 
5. Autoimmune hepatitis 
6. Hemochromatosis 
7. Wilson’s disease 
8. Alpha1 anti-trypsin deficiency 
 
NONHEPATIC CAUSES 
1. Celiac sprue 
2. Inherited disorders of muscle metabolism 
3. Strenuous exercise 
Common Agents That Can Cause Liver 
 Transaminase  Elevations Elevations 
Medications Herbal supplements/vitamins 
Acetaminophen Chaparral leaf 
Amiodarone  Ephedra 
Amoxicillin- clavulanic acid Gentian 
Carbamazepine  Germander 
Fluconazole  Jin bu huan 
Glyburide  Kava 
Heparin Scutellaria (skullcap) 
Isoniazid (INH) Senna 
Ketoconazole  Shark cartilage 
Labetalol  Vitamin A 
Nitrofurantoin   
Nonsteroidal anti-inflammatory drugs  
Phenytoin  
Protease inhibitors 
Sulfonamides 
Trazodone  
Information from reference (24). 
Chronic liver diseases linked with Sr. 
 Aminotransferases: 
1.Alcoholic liver disease and serum transaminases. 
      Excessive alcohol intake can lead to both acute and chronic liver 
injury. A mildly elevated level of serum aminotransferase with an AST-
ALT ratio of 2:1 is highly suggestive of alcoholic liver injury. In one 
study (25), more than 90% of patients with an AST-ALT ratio of at 
least 2:1 had alcoholic liver disease, and more than 96% of patients 
with a ratio of at least 3:1 had alcoholic liver disease. Besides the AST-
ALT ratio, an elevated Sr. GGT level is often useful in the diagnosis of 
alcoholic liver disease. However, the liver response that regulates Sr. 
GGT levels in the body is extremely sensitive, and the level of Sr. GGT 
may become elevated with even moderate consumption of alcohol. The 
reported sensitivity of an elevated Sr. GGT level for the detection of 
alcohol ingestion is 52% to 94% (24).  
Alcoholic liver disease ranges from fatty liver to alcoholic 
hepatitis to alcoholic cirrhosis. Patients with fatty liver and alcoholic 
hepatitis often experience remarkable reversal in liver histopathologic 
characteristics and clinical symptoms with alcohol cessation.  
 
 
2. Hepatitis C and serum transaminases.  
         The diagnosis of hepatitis C is often made after routine 
measurement of liver enzymes reveals elevated levels. However, HCV 
infection may progress to decompensated cirrhosis and hepatocellular 
carcinoma in a significant proportion of patients. Known risk factors for 
HCV infection include blood transfusions before 1992 (before initiation 
of routine HCV antibody screening of the blood supply), injecting drug 
use, needle-stick injuries, long-term hemodialysis, and a history of 
multiple sexual partners. Of these risk factors, injecting drug use 
carries the highest risk. A study of middle-class drug abusers in Rhode 
Island (27) determined that 76.7% of all patients who admitted to 
injecting drug use tested positive for HCV--an odds ratio of 22.6. Of 
persons exposed to HCV, 85% experience chronic infection. A positive 
HCV antibody test using a second-generation enzyme-linked 
immunosorbent assay (ELISA) in a person with risk factors for HCV 
usually suggests ongoing infection, although a confirmatory test is 
always recommended. In patients who deny the risk factors stated 
previously, the relatively inexpensive recombinant immunoblot assay 
(RIBA) might be a useful confirmatory test, since almost all persons 
with chronic infection have RIBA test results positive for HCV. 
However, in persons with one or more risk factors for HCV, a 
qualitative polymerase chain reaction test for detection of HCV RNA in 
serum is the recommended confirmatory(26,27). 
3. Hepatitis B and serum transaminases. 
          In highly endemic areas, such as Asia and Africa, up to 15% of 
the population are long-term HBV carriers. The main routes of 
transmission in these areas are perinatal transmission (exposure to 
infected vaginal tract secretions and blood during labor) and horizontal 
transmission in childhood. The likelihood of chronic infection among 
persons exposed to HBV is inversely related to age: up to 95% of those 
infected at an age less than 5 years have chronic HBV infection (28). 
The risk is especially great if a child's mother has active hepatitis B 
viral replication; moreover, the risk is directly proportional to her level 
of viremia. By comparison, the risk of chronic infection is less than 5% 
among adults exposed to this virus. In primary care clinics, neonatally 
acquired hepatitis B is generally detected through screening tests in 
high-risk patients, whereas adult-onset hepatitis B is often not 
detected until clinical signs of chronic liver disease develop. Serologic 
markers for HBV infection include hepatitis B surface antigen (HBsAg), 
antibody to hepatitis B surface antigen (anti-HBs), antibody to 
hepatitis B core antigen (anti-HBc), hepatitis B e antigen (HBeAg), and 
antibody to HBeAg (anti-HBe). Although these tests are helpful, serum 
HBV DNA testing is important to completely evaluate a patient with 
chronic HBV infection.  
 
4. Autoimmune hepatitis and serum transaminases. 
         Autoimmune hepatitis should be included in the differential 
diagnosis of any patient with chronically elevated liver test results, 
particularly because autoimmune hepatitis is amenable to therapy. 
Type 1 autoimmune hepatitis, the most common form, typically occurs 
in young to middle-aged women. The female-male ratio is 4:1. About 
30% of patients present with acute symptoms and laboratory 
derangements, ranging from hyperbilirubinemia to striking elevations 
in levels of serum aminotransferase. Some patients with autoimmune 
hepatitis are asymptomatic and have only modest elevation of serum 
liver enzyme levels. There may be an association between autoimmune 
hepatitis and other autoimmune diseases, such as thyroiditis and 
rheumatoid arthritis (24).  
The diagnosis of autoimmune hepatitis is suggested by serum 
tests that are positive for antinuclear antibodies, anti-smooth muscle 
antibodies, or hypergammaglobulinemia (an elevated gamma-globulin 
fraction on serum protein electrophoresis). A liver biopsy showing 
periportal inflammation, interface hepatitis, increased bridging 
necrosis, and diffuse infiltration of predominantly plasma cells confirms 
the diagnosis.  
5. Hemochromatosis and serum transaminases. 
Hereditary hemochromatosis is an autosomal recessive condition that 
primarily affects persons of Northern European ancestry. Hereditary 
hemochromatosis is characterized by excessive gastrointestinal 
absorption of iron from a normal diet and subsequent iron deposition in 
the liver, heart, pancreas, anterior pituitary, skin, and joints. Although 
women may experience all the manifestations of iron overload, the 
degree of iron loading is usually lower in women than in men because 
of physiologic blood loss from menstruation.  
          Elevated Sr. Aminotransferase levels may prompt testing for 
hemochromatosis, but many patients, even those with marked iron 
overload, have normal liver enzyme levels. The diagnosis of 
hemochromatosis should be suspected in patients with elevated Sr. 
transferrin-iron saturation (>45%) or an elevated Sr. ferritin 
concentration (ferritin, >200 ng/mL in women, >300 ng/mL in men), 
or both. Liver biopsy findings include increased stainable iron in 
hepatocytes (rather than Kupffer cells) with the greatest density of 
iron in periportal rather than pericentral hepatocytes. A hepatic iron 
concentration greater than 4,000 micrograms/g of liver dry weight and 
a hepatic iron index (hepatic iron concentration divided by age in 
years) greater than 1.9 are useful to distinguish homozygotes from 
heterozygotes and to identify patients with alcoholic liver disease who 
have compensated liver disease (29). However, the hepatic iron 
concentration and hepatic iron index are not "gold standards" for the 
diagnosis of hereditary hemochromatosis. They may be low in 
homozygotes with mild or minimal phenotypic expression or high in 
patients with end-stage liver disease who do not have hereditary 
hemochromatosis.  
With the identification of the HFE gene mutation, the diagnosis of 
hereditary hemochromatosis can now be confirmed without a liver 
biopsy. Two HFE gene mutations were originally described: a "major" 
mutation involving a cysteine-to-tyrosine substitution at position 282 
(C282Y) and a "minor" mutation involving a histidine-to-aspartate 
substitution at position 63 (H63D) mutations(30).  
6. Simple steatosis and nonalcoholic steatohepatitis. 
         Nonalcoholic fatty liver disease comprises a spectrum from 
steatosis to NASH. The term simple steatosis is used to describe fatty 
deposition in the liver without the necroinflammatory changes or 
fibrosis, or both, that are present in NASH. Although steatosis and 
NASH may be associated with elevated Sr. Aminotransferase levels, the 
natural history in these two entities is thought to be different. 
Steatosis is generally considered a benign and nonprogressive 
condition, whereas NASH may be associated with progressive injury 
that leads to fibrosis and cirrhosis in some patients. The most common 
risk factors for NASH include obesity (body mass index, ≥30), type 2 
diabetes mellitus, hypertriglyceridemia, use of a variety of medications 
or toxins, and jejunoileal bypass (31).  
A detailed alcohol history needs to be obtained before a 
diagnosis of NASH is considered, because NASH may be histologically 
indistinguishable from Alcoholic liver disease. Serum levels of AST and 
ALT may aid the physician in differentiating NASH from alcoholic liver 
disease, because patients with NASH usually do not have a greatly 
increased AST-ALT ratio. Although imaging studies such as ultrasound 
or computed tomography may suggest fatty infiltration of the liver, a 
biopsy is necessary to definitively establish the diagnosis.   
NASH is now recognized as a cause of cryptogenic cirrhosis, 
because there are no serologic markers for NASH and the characteristic 
findings of hepatic fatty infiltration and necroinflammation may 
disappear in late stages of the disease. Several recent studies (32,33) 
have found an increased prevalence of diabetes and obesity among 
patients with cryptogenic cirrhosis compared with patients who have 
cirrhosis from known causes. This evidence suggests that NASH may be 
an important etiologic factor in cryptogenic cirrhosis.  
OBESITY AS A RISK FACTOR 
Obesity and overweight are the most prevalent nutritional 
disorders among children and adults. Currently available data suggests 
that approximately 40% of children in the United States are 
overweight or obese, the prevalence of obesity is highest among 
specific ethnic groups(34,35). Data regarding the Indian population is 
not available. Obesity predisposes to a number of metabolic disorders 
like insulin resistance, type II diabetes mellitus, hypertension, 
hyperlipidemia, liver and renal dysfunction, reproductive dysfunction 
and the most important coronary artery disease(36,37). 
AIM OF THE STUDY 
Obesity is the major cause of elevated Sr. Transaminases in 
asymptomatic subjects. Whether there is direct association between 
BMI and Sr. Transaminases is not clear. The aim of this study is to 
evaluate the Sr.  Transaminase levels in 60 asymptomatic women, with 
simple obesity. 
 
  
 
 
 
 
  
 
 
REVIEW OF LITERATURE 
LIVER ENZYME TESTS 
The battery of liver enzymes includes Alanine and Aspartate 
aminotransferases (ALT and AST), Alkaline phosphatase (ALP) and 
Gamma-glutamyltransferase (GGT)(1,38). Normal ranges are based on 
distributions from “healthy” volunteers. The upper limit of normal 
(ULN) is defined as the mean + 2 SD, which implies that 2.5% of the 
liver tests from these healthy persons exceed the ULN. The Sr. 
Aminotransferases catalyze the reversible transformation of á-
ketoacids into amino acids. Their serum levels reflect the amount of 
hepatocellular injury and death on a day-by-day basis. 
Aminotransferases (and predominantly AST) are not only found in 
hepatocytes but also in other tissues (heart and skeletal muscles, 
kidney, brain, pancreas, lung, and red blood cells). The liver contains 
400 U ALT/g protein (mainly cytoplasmic) and 500 U AST/g protein (> 
803 % contained in mitochondria and endoplasmic reticulum). Damage 
to one gram of liver tissue (or the membranes of 171 million 
hepatocytes) results in a significant increase in the serum ALT activity. 
Sr. AST responds in the same fashion, especially following liver cell 
necrosis and destruction of mitochondria and endoplasmic reticulum. 
Alkaline phosphatase is found in the biliary pole of the hepatocytes, the 
bile duct epithelia, osteoblasts, kidney, lung, intestine and placenta. 
The serum activity present in normal individuals is predominantly due 
to the izoenzymes of the liver, bone and kidney. Thus, an isolated rise 
in Sr. ALP is seen in the third trimester of preganancy, during growth 
(bone Sr. ALP) or may be due to intestinal Sr. ALP (following ingestion 
of a fatty meal). In cholestatic liver disease, the elevated bile acids 
stimulate the synthesis of Sr. ALP. Differentiation between hepatic and 
non-hepatic causes of Sr. ALP elevation can be done by determination 
of Sr. ALP isoenzymes or more easily by testing for Sr. GGT, which rises 
in liver but not in bone disease. Sr. GGT is found in hepatocytes, 
cholangiocytes, kidney, pancreas, epididymis, heart, lung, intestine, 
bone marrow, salivary glands, thymus, spleen and brain, which is an 
explanation for the lack of specificity for the diagnosis of hepatobiliary 
disease. Elevated values of Sr. GGT are caused by damage to cellular 
membranes, cellular regeneration or by enhanced synthesis as a result 
of induction of the biotransformation enzyme system. Known inducers 
are bile acids (cholestasis), prolonged regular abuse of alcohol and 
especially antiepileptic drugs (phenytoin, carbamazepine). A decline in 
Sr. GGT can be observed during oestrogen  administration or 
pregnancy. Due to the sudden release of intracellular reservoirs of 
aminotransferases and their short halflife 
(1 – 2 days), the levels of ALT and AST respond quickly to 
hepatocellular damage or acute bile duct obstruction. A rise in Sr. ALP 
and GGT occurs more slowly in response to cholestasis, and the levels 
are maintained longer due to a half-life of more than 4 days (41). 
Knowledge of these enzyme  
kinetics is important for the correct interpretation of abnormal liver 
enzymes as predominant hepatocellular or cholestatic patterns. 
PRINCIPLES OF DIAGNOSTIC ENZYMOLOGY 
All of the hundreds of different enzymes present in the human 
body are synthesized intracellularly and most of them carry out their 
functions within the cells in which they are formed. However, certain 
enzymes are secreted, either in an active or inactive form and, after 
activation, function within the extracellular fluids. We are principally 
concerned with the changes in the activity of serum or plasma of the 
enzymes that are predominantly intracellular and that are normally 
present in the serum in low activities only. By measuring changes in 
activities of these enzymes in disease, it is possible to infer the location 
and nature of pathological changes in tissues of body. Therefore it is 
necessary to understand the factors that affect the rate of release of 
enzymes from their cells of origin and the rate at which they are 
cleared from the circulation, so that changes in activity in disease can 
be interpreted correctly(38-41). 
 
 
FACTORS AFFECTING ENZYME LEVELS IN PLASMA OR 
SERUM. 
The measured level of activity of an enzyme in blood is the result 
of the balance between the rate at which it enters the circulation from 
its cells of origin and the rate at which it is inactivated or removed. 
ENTRY OF ENZYMES INTO THE BLOOD 
By far the most important factors that affect the enzyme 
activities in serum or plasma are those that influence the rate at which 
enzymes enter the circulation from the cells. These factors can be 
divided into two main categories: Those that affect the rates at which 
enzymes leak from cells, and those that reflect altered rates of enzyme 
production, due either to increased synthesis of a particular enzyme by 
individual cell types or to proliferation of a particular type of enzyme 
producing cell.(38-41) 
Leakage of enzymes from cells- Enzymes are retained 
within their cells of origin by the plasma membrane surrounding the 
cell. The plasma membrane is a metabolically active part of the cell, 
and its integrity depends on the cell’s energy production. Any process 
that impairs the energy production, either by depriving the cell of 
oxydizable substrates or restricting access of oxygen needed for 
energy production, will promote deterioration of the cell membrane. 
The membrane will become leaky and, if cellular injury becomes 
irreversible, the cell will die. Small molecules are the first to leak from 
damaged or dying cells followed by larger molecules such as enzymes; 
ultimately the whole contents of necrotic cells are discharged. 
Direct attack on the cell membranes by such agents as viruses or 
organic chemicals is an obvious cause of enzyme release and one that 
is particularly important in the case of the liver. A reduction in the 
supply of the oxygenated blood perfusing any tissue will promote 
enzyme release. The most obvious clinical condition in which such a 
reduction occurs is myocardial infarction(23). The cells of the affected 
region rapidly begin to deteriorate and die, releasing their enzyme 
contents. Transfer of the enzymes to the extracellular fluids and 
lymphatics and then to the systemic circulation accounts for the rapid 
rise in serum enzyme activity that is characteristic of this condition. 
The liver is very sensitive to hypoxia, which can result from diminished 
cardiac output (heart failure). Increased activities of hepatocellular 
enzymes in the blood accompany a wide variety of conditions such as 
congestive heart failure, shock and hypoxia.  
Because of the very high concentrations of enzymes within the 
cells, thousands or even ten-thousand times greater than the 
concentrations in extracellular fluid, and because of the sensitivity with 
which small amounts of enzyme can be detected by their catalytic 
activity, an increase of enzyme activity in the extracellular fluid or 
plasma is an extremely sensitive indicator of even minor cellular 
damage. 
Enzyme changes reflecting altered enzyme production. 
The small amounts of intracellular enzymes normally present in the 
plasma can be assumed to result from turn over of cells or leakage of 
enzymes from healthy cells. This contribution of enzymes to the 
circulating blood may decrease, either as a result of genetic deficiency 
of enzyme production or when enzyme production is depressed as a 
result of disease. However, cases in which enzyme production is 
increased are of more general interest in diagnostic enzymology. 
For example, an increase in the number and activity of the 
Alkaline phosphatase- producing osteoblast of bone is responsible for 
the increased level of the alkaline phosphatase in the serum of 
normally growing children. Increased osteoblastic activity also 
accounts for the increase levels of this enzyme in serum in various 
types of bone disease. Towards the end of normal pregnancy, the 
placenta constitutes a new source of Alkaline phosphatase and 
contributes its characteristic iso-enzyme to the maternal circulation. 
Enzyme induction may increase enzyme production; an 
example of such induction is the increased activity of Gamma glutamyl 
transferase in serum, which may result from the administration of 
drugs such as Barbiturates or Phenytoin and from intake of alcohol. 
Biliary obstruction causes increase synthesis of Alkaline phosphatase in 
the liver. 
CLEARANCE OF ENZYMES 
Little is known about the way in which enzymes are cleared from 
the circulation from the circulation. Few enzyme molecules are small 
enough to pass through the healthy glomeruli of the kidney, and 
therefore urinary excretion is not a major route for elimination of 
enzymes from the circulation. An exception to this is Amylase; 
increased levels of this enzyme in the blood (e.g. ,  following acute 
pancreatitis) are accompanied by increased excretion in the urine. 
Present evidence suggest that enzyme inactivation begins in the 
plasma and that inactivated enzymes are rapidly removed probably by 
the reticuloendothelial system. The half life (t 1/2) of an enzyme in 
plasma may be a few hours or several days, but in most cases an 
average half life of 24 to 48 hours can be expected(39,40). 
The existence of circulating inhibitors or activators of enzymes 
has little effect on activities measured in the laboratory. When these 
inhibitors are of a reversible nature, the relatively high dilutions of 
serum used in most modern enzyme assays are sufficient to eliminate 
any possible effects from this cause. 
 
 
 
THE SERUM TRANSAMINASES 
1.    ASPARTATE TRANSAMINASE; ASPARTATE 
AMINOTRANSFERASE, ( AST, GLUTAMATE 
OXALOACETATE TRANSAMINASE, GOT ) 
2. ALANINE TRANSAMINASE; ALANINE 
AMINOTRANSFERASE,  
             ( ALT, GLUTAMATE  PYRUVATE TRANSAMINASE, GOT 
) (20) 
The aminotransferases are a group of enzymes that catalyse the 
interconversion of the amino acids and the alpha-oxy acids by transfer 
of amino groups. Distinct isoenzymes of aspartate transaminase are 
present in the cytoplasm and the mitochondria of cells. For example, in 
conditions associated with mild degree of liver tissue injury, the 
predominant isoenzyme form in serum is that from the cytoplasm. 
Although some mitochondrial isoenzymes is also present. Severe tissue 
damage results in the release of much mitochondrial isoenzyme as 
well. 
The Alpha-oxoglutarate / L-glutamate couple serves as one 
amino group acceptor and donor pair in all amino-transfer reactions; 
the specificity of the individual of the individual enzymes derives from 
the particular amino acid that serves as the other donor od an amino 
group. Thus Aspartate aminotransferase catalyses the reaction shown 
in the equation no (1). 
 
  (1)          L-Aspartate + α-Oxoglutarate Æ Oxaloacetate + L-
Glutamate 
Alanine aminotransferase catalyses the analogous reaction 
presented in equation no: (2) 
   (2)          L-Alanine + α-Oxoglutarate Æ Pyruvate + L-Glutamate 
The reactions are reversible, but the equilibria of the AST and 
ALT reactions favour formation of Aspartate and Alanine respectively. 
CLINICAL SIGNIFICANCE 
The serum transaminases are widely distributed in human 
tissues. Both AST and ALT are normally present in human plasma, bile, 
cerebrospinal fluid and saliva but none is found in urine unless a kidney 
lesion is present. 
In viral hepatitis and other forms of liver disease associated with 
hepatic necrosis, levels of Sr. AST and ALT are elevated even before 
clinical signs and symptoms of disease such as jaundice appear. 
Activities of both enzymes may reach values as high as hundred times 
the upper reference limit, twenty to fifty fold elevations are most 
frequently encountered. Peak values of transaminase activity are seen 
between the seventh and twelfth days; values return to normal levels 
by the third to fifth week if recovery is uneventful. In toxic or viral 
hepatitis, ALT is characteristically as high as or higher than AST, and 
the ALT/AST ratio, which normally is <1, approaches or becomes 
greater than 1. 
Moderately increased levels of AST and ALT activity may also be 
observed in extrahepatic cholestasis. Levels observed in cirrhosis vary 
with the status of the cirrhotic process; they range from upper normal 
to some 4-5 times normal, with the level of AST activity higher than 
that of ALT activity. Five to ten fold elevation of the two enzymes may 
occur in patients with primary or metastatic carcinoma of liver, with 
AST usually being higher than ALT, but levels are often normal in the 
early stages of malignant infiltration of liver. Slight or moderate 
elevations of both ALT and AST may be observed after intake of 
alcohol, during Delirium Tremens, and after administration of drugs 
such as opiates, salicylates, or ampicillin. 
Although serum levels of both AST and ALT become elevated 
whenever disease process affect liver cell integrity, ALT is more liver 
specific enzyme. Serum elevations of ALT activity are rarely observed in 
conditions other than parenchymal liver disease. Moreover, elevations 
of ALT activity persist longer than do those of AST activity. 
 
Sensitivity and specificity of ALT for the detection of liver disease 
is around 83 % (42-44, 24). An isolated rise in ALT is of hepatocellular 
origin, after exclusion of macroenzyme-I-immune complexes. The 
diagnostic sensitivity of AST is significantly lower (70%) and less 
specific. The study of the AST: ALT ratio (or De-Rits ratio) can yield 
some additional information but specific etiologic diagnosis cannot 
usually be based on these routine tests or ratio’s. In alcoholic liver 
disease the AST: ALT ratio is greater than 2:1, due to a 
alcohol-related deficiency of pyridoxal 5-phosphate (vitamin B6).  
METHODS FOR THE MEASUREMENT OF 
TRANSAMINASES ACTIVITY 
The assay system for measuring transaminase activity contains 
two amino acids and two oxo-acids as shown in equations (1) and (2). 
There is no convenient method for assaying either of the amino acids in 
the reaction system, therefore formation or consumption of the oxo-
acids is measured(47). 
TEST PRINCIPLE USED TO ESTIMATE SERUM AST LEVELS 
The method is according to the International Federation of 
Clinical Chemistry (IFCC)(47). AST in the sample catalyses the transfer 
of an amino group between L-Aspartate and 2-oxoglutarate to form 
Oxaloacetate and L-Glutamate. The Oxaloacetate then reacts with 
NADH in the presence of Malate Dehydrogenase (MDH) , to form NAD+. 
(3) L-Aspartate + 2-Oxoglutarate               Oxaloacetate + L-
Glutamate 
(4)  Oxaloacetate + NADH + H+                    L-Malate + NAD+ 
The rate of the NADH oxidation is directly proportional to the 
catalytic AST activity. It is determined by measuring the decrease in 
absorbance at 340nm(45,46). 
TEST PRINCIPLE USED TO ESTIMATE SERUM ALT LEVELS 
The method is according to the International Federation of 
Clinical Chemistry (IFCC)(47). ALT in the sample catalyses the transfer 
of an amino group between L-Alanine and 2-oxoglutarate to form 
Pyruvate and L-Glutamate. The Pyruvate formed is reduced by NADH in 
a reaction catalysed by Lactate Dehydrogenase (LDH) to form L-
Lactate and NAD+(48). 
L-Alanine + 2-Oxoglutarate                      Pyruvate + L-Glutamate 
Pyruvate + NADH + H+                       L-Lactate + NAD+ 
The rate of the NADH oxidation is directly proportional to the 
catalytic ALT activity. It is determined by measuring the decrease in 
absorbance at 340nm(45,46). 
REFERENCE RANGES(48) 
1.  ASPARTATE TRANSAMINASE  
For MALES- UPTO 38 UNITS/L 
For FEMALES- UPTO 32 UNITS/L 
 2.  ALANINE TRANSAMINASE 
For MALES- UPTO 41 UNITS/L 
For FEMALES- UPTO 31UNITS/L 
OBESITY; 
DEFINITION- Overweight and obesity are defined as abnormal or 
excessive fat accumulation that may impair health. 
BODY MASS INDEX 
Body mass index (BMI) is a simple index of weight-for-height 
that is commonly used in classifying overweight and obesity in adult 
populations and individuals. It is defined as the weight in kilograms 
divided by the square of the height in meters (kg/m2). 
BMI provides the most useful population-level measure of 
overweight and obesity as it is the same for both sexes and for all ages 
of adults. However, it should be considered as a rough guide because it 
may not correspond to the same degree of fatness in different 
individuals. 
The World Health Organization (WHO) defines "overweight" as a 
BMI equal to or more than 25, and "obesity" as a BMI equal to or more 
than 30 (37). 
Waist Circumference and Waist to Hip Ratio 
           Determining waist circumference eliminates the inconsistencies 
of the BMI. Waist circumference measurement is an important part of 
determining obesity and morbid obesity. A waist circumference of 40 
inches in men and 35 inches in women is an indication of obesity. 
           Waist to hip ratio is also used as a guideline for determining 
obesity. This measurement determines how weight is distributed on 
the body. Weight distribution on the lower half of the body (pear-
shape) generally does not pose the same serious consequences as 
weight that crowds the abdominal area. Hip to waist ratio is calculated 
by dividing the circumference of the waist by the circumference of the 
hips. A healthy waist to hip ratio for women is 0.80 or less. For men, 
0.90 or less is a healthy waist to hip ratio. Anything over 1.0 is 
considered obese(49-52). 
COMPLICATIONS OF OBESITY(53-55). 
1. Insulin resistance and type II diabetes mellitus 
2. Reproductive disorders 
3. Hypertension 
4. Dyslipidaemia 
5. Cardiovascular disease 
6. Obstructive sleep apnoea 
7. Bone, joint and cutaneous disease 
8. Non alcoholic fatty liver disease 
9. Ovarian hyperandrogenism and gynaecomastia 
10. Emotional and psychological sequalae 
11. Focal glomerulosclerosis 
12. Cholecystitis and gall stones 
13. Polycystic ovarian syndrome 
 
 
 
 
 
CLASSIFICATION OF OBESITY 
WHO 
Classification  
Popular 
Description  
BMI 
(kg/m2) 
Risk of co-
morbidities 
Underweight  Thin  <18.5  Low (but risk 
of other 
clinical 
problems 
increased) 
Normal 
range  
Normal  18.5 - 24.9  Average 
Overweight    > 25.0   
    Pre-obese  Overweight  25 - 29.9  Increased 
    Obese Class I  Obese  30.0 - 34.9  Moderate 
    Obese Class II  Obese  35.0 - 39.9  Severe 
   Obese ClassIII  Morbidly 
Obese  
> 40.0  Very severe 
NOTE: In our study which was conducted between August 2006 – 
August 2008, we have included women with BMI of ≥ 30, considering a 
BMI ≥ 30 as obese according to WHO Obesity definition. In November 
2008, India has released its revised BMI standards, specifically tailored 
for the Indian population. According to the Revised standards, BMI ≥ 
23 is defined overweight and BMI ≥ 25 is defined obese.  
ETIOLOGICAL CLASSIFICATION (56,37) 
SIMPLE OBESITY 
1. Familial 
2. Diet induced  
OBESITY DUE TO GENETIC SYNDROMES AND 
HORMONAL DISTURBANCES 
1. Downs syndrome 
2. Turners syndrome 
3. Cohens syndrome 
4. Laurence Moon-Biedl syndrome 
5. Pseudohypoparathyroidism 
6. Prader Willi syndrome 
7. Growth hormone deficiency 
8. Growth hormone resistance 
9. Hypothyroidism 
          10. Cushings syndrome 
11. Precocious puberty 
 
DRUG INDUCED OBESITY 
1. Cortisol and other Glucocorticoids 
2. Tricyclic antidepressants 
3. Monoamine oxidase inhibitors 
4. Oral contraceptives 
5. Insulin (in excessive doses) 
6. Thiazolidinediones 
7. Risperidone 
8. Clozapine 
OBESITY AND NONALCOHOLIC FATTY LIVER 
DISEASE 
Nonalcoholic Fatty Liver disease (NAFLD) is an emerging clinical 
problem among obese subjects particularly those with central obesity. 
40% of patients with NAFLD are overweight or obese, 20% have type 
2 diabetes and 20% dyslipidemic( See Pie chart ). 
 
NAFLD ETIOLOGY
40%
20%
20%
20%
OBESITY
TYPE II DM
DYSLIPIDEMIA
OTHERS
 
 The development of the characteristic pathological changes 
within the liver are intimately related to the various clinical and 
biological markers of the metabolic syndrome - BMI, waist 
circumference, hyperinsulinaemia, hypertriglyceridaemia, and impaired 
glucose tolerance. The diagnosis of NAFLD rests on characteristic 
histolological features that include substantial fat infiltration, 
necroinflammation and fibrosis in the absence of alcohol as a cause for 
the disease. In NAFLD the ratio of serum alanine transaminase (ALT) to 
aspartate transaminase (AST) is always >1 whereas the ratio in 
alcoholic liver disease is almost always <145. Histological evidence of 
fibrosis and/or cirrhosis is seen in up to 50% of patients with most 
patients, who initially show fibrosis, developing cirrhosis after 10 years 
- it has been suggested that "cryptogenic cirrhosis" represents "burnt 
out" NAFLD. A liver biopsy is necessary to make a diagnosis and is 
important for therapeutic and prognostic reasons - ultrasound 
scanning of the liver is not sufficiently sensitive to be diagnostic. 
          The causative factors inducing necrosis, inflammation and 
fibrosis within the liver include oxidative stress and subsequent lipid 
peroxidation, factors associated with abnormal cytokine production 
and factors associated with disordered fat metabolism and insulin 
resistance. 
   The two metabolic abnormalities most strongly associated 
with NAFLD are insulin resistance and an increase supply of free fatty 
acids to the liver (see section 2.1 ). There is evidence that NAFLD 
associated with obesity and type 2 diabetes is due primarily to 
peripheral insulin resistance and consequential hyperinsulinaemia. 
Insulin blocks hepatic mitochondrial fatty acid oxidation and results in 
an increased concentration of intracellular fatty acids that may be 
directly toxic or lead to oxidative stress. The link between central 
obesity and liver injury may be explained by the fact that fatty acids 
are mobilised more rapidly from visceral (central) than subcutaneous 
fat and drain directly to the liver via the portal vein. 
  Weight loss is generally associated with a reduction in the 
severity of the biochemical abnormalities and a regression of the 
steatosis. Nevertheless, sudden weight loss or "weight cycling" (weight 
loss followed by weight regain) may predispose to NAFLD(57,58). 
PATHOGENESIS(59-68) 
It is not yet understood why simple steatosis develops in some 
patients with obesity, whereas steatohepatitis and progressive disease 
develops in others; differences in body-fat distribution or anti-oxidant 
systems, possibly in the context of a genetic predisposition, may be 
among the explanations. 
A net retention of lipids within the hepatocytes, mostly in the 
form of triglycerides, is a prerequisite for the development of 
nonalcoholic fatty liver disease. The primary metabolic abnormalities 
leading to lipid accumulation are not well understood, but they could 
consists of alterations in the pathways of uptake, synthesis, 
degradation, or secretion in hepatic lipid metabolism resulting from 
insulin resistance. 
Insulin resistance is the most reproducible factor in the 
development of nonalcoholic fatty liver disease. The molecular 
pathogenesis of insulin resistance seems to be multifactorial, and 
several molecular targets involved in the inhibition of insulin action 
have been identified. These include Rad ( ras 
 associated with diabetes), which interferes with essential cell 
functions (growth, differentiation, vesicular transport, and signal 
transduction ); PC-1 (a membrane glycoprotein that has a role in 
insulin resistance ), which reduces insulin-stimulated tyrosine kinase 
activity; leptin, which induces dephosphorylation of insulin-receptor 
substrate-1; fatty acids, which inhibit insulin-stimulated peripheral 
glucose uptake; and tumour necrosis factor, which down regulates 
insulin-induced phosphorylation of insulin receptor substrate-1 and 
reduces the expression of insulin dependant glucose-transport 
molecule Glu4. Insulin resistance leads to fat accumulation in the 
hepatocytes by two main mechanisms; lipolysis and dyslipidemia. 
Clinically significant amounts of dicarboxylic acids, which are 
potentially cytotoxic, can be formed by microsomal oxidation. This 
pathway of fatty acid metabolism is closely related to mitochondrial 
oxidation and peroxisomal oxidation. Deficiency of the enzymes of 
peroxisomal oxidation has been recognized as an important cause of 
micro-vesicular steatosis and steatohepatitis. Deficiency of the acyl-
coenzyme-A oxidase disrupts the oxidation of very-long-chain-fatty 
acids and diacryboxylic fatty acids, leading to extensive microvesicular 
steatosis and steatohepatitis. Loss of this enzyme also causes 
sustained hyperactivation of peroxisome-proliferator-activated 
receptor alpha, leading to transcriptional up-regulation of PPAR-alpha-
regulated genes. PPAR-alpha has been implicated in promoting hepatic 
synthesis of uncoupling protein2, which is expressed in the liver of 
patients with nonalcoholic fatty liver disease.  
Increased intrahepatic levels of fatty acids provide a source of 
oxidative stress, which may in large part be responsible for the 
progression from steatosis to steatohepatitis to cirrhosis. Mitochondria 
are the main cellular source of reactive oxygen species, which may 
trigger steatohepatitis and fibrosis by three main mechanisms: lipid 
peroxidation, cytokine induction, and induction of Fas ligand. 
Patients with steatohepatitis have ultrastructural mitochondrial 
lesions, including linear crystalline inclusions in megamitochondria. 
This mitochondrial injury is absent in most patients with simple 
steatosis and in healthy subjects. Patients with steatohepatitis slowly 
resynthesize ATP in vivo after a fructose challenge, which causes acute 
hepatic ATP depletion. This impaired ATP recovery may reflect the 
mitochondrial injury found in patients with steatohepatitis. 
Thus although symptoms are liver disease develop rarely in 
patients with fatty liver who are obese, the steatotic liver may be 
vulnerable to further injury when challenged by additional insults. This 
has led to the presumption that progression from simple steatosis to 
steatohepatitis and to advanced fibrosis results from two distinct 
events. First, insulin resistance leads to accumulation of fat within 
hepatocytes, and second, mitochondrial reactive oxygen species cause 
lipid peroxidation, cytokine induction, and the induction of Fas ligand. 
IMAGING STUDIES 
On ultrasonography, fatty infiltration of the liver produces a 
diffuse increase in echogenecity as compared with that of the kidneys. 
Regardless of the cause, cirrhosis has similar appearance on 
ultrasonography. Ultrasonography has a sensitivity of 89% and a 
specificity of 93% in detecting steatosis and a sensitivity and 
specificity of 77% and 89%, respectively, in detecting increased 
fibrosis.(69) 
Fatty infiltration of the liver produces a low density hepatic 
parenchyma on computed tomographic ( CT ) scanning. Steatosis is 
diffuse in most patients with nonalcoholic fatty liver disease, but 
occasionally it is focal. Consequently, ultrasonography and CT scans 
may be misinterpreted as showing malignant liver masses(70). In such 
cases, magnetic resonance imaging can distinguish space occupying 
lesions from focal fatty infiltration ( characterized by isolated areas of 
fat infiltration ) or focal fatty sparing ( characterized by isolated areas 
of fatty liver )(71). Magnetic resonance spectroscopy allows a 
quantitative assessment of fatty infiltration of liver due to obesity or 
any other cause(72). 
 
 
 
 
  
 
 
 
 
MATERIALS AND METHODS; 
 
 This study was carried out in 60 ASYPMTOMATIC OBESE WOMEN  
who 
 came for routine MASTER HEALTH CHECK UP between August 2006 
and August 2008, in PSG Hospitals, Coimbatore. 
 
Women subjects were primarily chosen, to rule out alcohol as a 
causative factor, for the changes in levels of serum transaminases.  
 
 All patients were screened according to a protocol consisting of a  
 
complete medical history, medical examination, BMI, Waist 
circumference, 
 
Liver function tests, other standardized blood tests, Ultrasonography of 
the 
 
abdomen.  
 
         Obesity  was defined as a Body mass index ( weight in kilograms 
divided  
 
by square of his or her height in metres) of 30 or more. 
 
 Routine laboratory investigations included a complete blood 
count, erythrocyte sedimentation rate, urea, creatinine, Fasting and 
post prandial blood glucose, Fasting total cholesterol, and Liver 
function tests. Other investigations included ECG, Chest X-ray. 
 
 
TOTAL CHOLESTEROL VALUES 
 
TOTAL   CHOLESTEROL  
<200 (5.17) Desirable 
200 – 239 (5.17-6.18) Borderline high 
≥240 (≥6.21) High 
 Serum Transaminases were estimated using IFCC () methods 
using COBAS INTEGRA DEVICE(47). 
          Analyses were adjusted for the effects of age at screening,  BMI, 
total cholesterol level or the presence or absence of fatty liver 
in Ultrasonography of the abdomen.   
EXCLUSION CRITERIA ; 
1. Diabetes Mellitus Type I or type II. 
2. Pre-existing or present evidence of liver or kidney or cardiac 
disease. 
3. Pregnant women. 
4. Patients on any drugs that impair the liver function. 
5. History or evidence of any endocrine disorders. 
6. History or evidence of any hormonal disturbances. 
7. History of alcohol use. 
8. History of fever or hospital admissions recently. 
Determination of Serum Transaminase levels; 
 
      Blood was drawn as fasting samples participants into heparinised 
tubes.  
 
Serum transaminases were estimated by the automated device ( 
COBAS  
 
INTEGRA ) . Reference ranges for  Aspartate transaminase was up to 
32 U/L  
 
and Alanine transaminase was up to 31 U/L in females in our 
laboratory(48). 
 
 
Statistical analysis ; 
 
 It was perfomed using SPSS PC 11.5. Analysis was performed to 
find  
 
the effect of each variable. 
 
 
 
 
 
 
 
PROFORMA         
  
Sr. AST and ALT levels in asymptomatic obese women 
 
Name :    Age:                            Address: 
 
OP.No :                                        Sex: 
                                        
Presenting complaints if any: 
Significant Past History :                                                                                   
- Diabetes Mellitus 
- Dyslipidemia  or any drugs for dyslipidemia                                                        
- Hypertension                                                                   
- Pre-existing Liver disease                                                          
- Jaundice 
- Renal disease 
- Parenteral nutrition 
- Heart disease 
- Coronary artery disease 
- Hypothyroidism  
- Cushings syndrome or Pseudo Cushings syndrome 
- Any other genetic syndromes 
- Hormonal disturbances 
- Emotional disturbances 
- Blood or Blood products transfusion 
 
Personal history : 
- eating habits 
- sleep pattern smoking 
- alcohol 
Any previous hospital admissions: 
 
History of any drug intake: 
 
O/e 
General Physical Examination : -  
              Pallor      : Yes / No                                 Cyanosis        : Yes / No  
              Clubbing : Yes / No                                 Pedal Edema : Yes / No  
              Pulse:-             / min                   
              BP    :               /     mm  hg  
     Height:      BMI: 
 
     Weight:      Waist circumference: 
INVESTIGATIONS :- 
 COMPLETE BLOOD COUNT:  
Hb 
RBC       
WBC 
Platelets 
ESR 
Sr. Urea 
Sr. Creatinine       
Fasting blood glucose 
Post prandial blood glucose 
Urine examination 
Fasting Total cholesterol:  
Sr. AST :-   
Sr. ALT :-  
CXR :          
ECG  :          
ULTRASOUND OF ABDOMEN:  
Inference      :-  
 
RESULTS 
SERUM TRANSAMINASE LEVELS IN STUDY SUBJECTS 
NO AGE BMI AST ALT TOTAL 
CHOL 
FATTY 
LIVER 
1. 37 30.4 45 47 254 P 
2. 43 32.3 41 39 239 P 
3. 64 31 56 49 247 P 
4. 47 31.6 21 18 156 A 
5. 37 32.4 66 111 272 P 
6. 47 30.8 31 42 200 P 
7. 45 31 27 28 192 A 
8. 59 31.4 88 67 265 P 
9. 41 32 78 98 234 P 
10. 53 30.7 59 65 311 P 
11. 52 30.6 48 57 289 P 
12. 51 31.8 20 31 212 A 
13. 35 32.8 61 47 323 P 
14. 31 30.1 31 37 278 P 
15. 43 30 39 56 167 A 
 
S.NO AGE BMI AST ALT TOTAL 
CHOL 
FATTY 
LIVER 
16. 64 31.1 41 33 222 P 
17. 35 32.4 39 56 256 P 
18. 47 30.2 18 43 250 A 
19. 39 31.5 50 57 198 P 
20. 56 32.6 76 34 244 P 
21. 33 31.8 46 79 264 P 
22. 62 30.4 34 44 260 P 
23. 57 33.8 22 18 240 P 
24. 49 31.6 80 112 257 P 
25. 39 32.7 33 48 215 P 
26. 41 31.5 26 33 178 A 
27. 50 32.8 64 59 259 A 
28. 22 30.6 21 18 190 P 
29. 61 31.4 120 79 278 P 
30. 36 31.8 50 68 299 P 
31. 47 32.3 23 26 232 A 
32. 55 30.6 66 45 343 P 
33. 38 32.6 74 63 287 P 
S.NO AGE BMI AST ALT TOTAL 
CHOL 
FATTY 
LIVER 
34. 58 30.7 77 48 181 P 
35. 34 32.2 35 36 231 A 
36. 68 31.8 48 90 276 P 
37. 40 32 64 63 320 P 
38. 31 31 20 24 152 A 
39. 58 31.7 31 18 260 A 
40. 51 30.9 47 39 282 A 
41. 29 31.6 50 41 194 P 
42. 39 30.8 18 22 123 A 
43. 53 30.1 39 58 254 P 
44. 63 32.7 44 68 324 P 
45. 50 33 74 66 259 P 
46. 45 32.8 40 66 239 P 
47. 53 30.6 87 50 257 A 
48. 37 31 17 22 219 A 
49. 35 33.4 60 142 183 P 
50. 55 31.7 33 34 240 A 
 
S.NO AGE BMI AST ALT TOTAL 
CHOL 
FATTY 
LIVER 
51. 28 32.8 55 87 232 P 
52. 34 31.7 18 35 164 A 
53. 49 31.8 39 57 252 A 
54. 38 30.8 16 25 184 A 
55. 43 30.7 49 87 285 P 
56. 56 31.5 111 85 251 P 
57. 69 32.6 23 27 256 A 
58. 54 30 58 94 275 A 
59. 39 32.7 85 79 282 P 
60. 42 32 50 43 240 P 
 
* P- FATTY LIVER PRESENT **A- FATTY LIVER ABSENT 
 
 
 
 
 
 
 
 
 
DISCUSSION ; 
 Between August 2006 and August 2008, 60 women subjects who 
attended the “ MASTER HEALTH CHECK UP” were identified and 
included in this study. Only women were included, primarily because to 
rule out, the influence of alcohol for the changes in Sr. Transaminases, 
since very few women consume alcohol in our country. All the subjects 
who attended the   “ MASTER HEALTH CHECK UP” were asymptomatic 
and just routinely came for check up programs. 
 Sr. Transaminases were estimated using International Federation 
of Clinical Chemistry ( IFCC ). 
DATA ANALYSIS 
 Of the total subjects 60, the number of subjects with elevated 
Serum Transaminases were totally 43. 
17
28%
43
72%
NORMAL TRANSAMINASES
ELEVATED TRANSAMINASES
 
 
 Out of the 43 subjects who had elevated Transaminases, both Sr. 
AST and Sr. ALT were elevated in 38 subjects. Only Sr. AST was 
elevated in 1 subject. Only Sr. ALT was elevated in 4 subjects. 
 
 Of the 60 women, 39 subjects had Fatty Liver in 
Ultrasonography of the abdomen, and 38 out of 60 subjects had 
dyslipidemia. 
 
39
21
FATTY LIVER PRESENT
FATTY LIVER ABSENT
 
Figure 1: NO OF SUBJECTS WITH FATTY LIVER IN THE STUDY POPULATION. 
 
 
 
 
38
22
DYSLIPIDEMIA NORMAL CHOLESTEROL
 
 
Figure 2: NO OF SUBJECTS WITH DYSLIPIDEMIA IN THE STUDY POPULATION. 
 The total number of subjects with Fatty liver amongst the 
subjects with elevated Sr. Transaminase levels were 35. Only 9 
subjects with elevated Sr. Transaminases did not show Fatty liver in 
Ultrasonography of the abdomen. 
 
PRESENCE OR ABSENCE OF FATTY LIVER 
AMONGST SUBJECTS WITH ELEVATED SERUM 
TRANSAMINASES LEVELS
35
80%
9
20%
FATTY LIVER
PRESENT
FATTY LIVER
ABSENT
 
Figure 3: NO OF SUBJECTS WITH FATTY LIVER AMONGST THE 43 SUBJECTS WITH 
ELEVATED SR. TRANSAMINASES. 
 
 
 
 
 Most of the patients with elevated Sr. Transaminase levels had 
Dyslipidemia. Only 10 subjects had a normal Total cholesterol level as 
compared to the 33 subjects who had Dyslipidemia. 
 
NO. OF SUBJECTS WITH NORMAL CHOLESTEROL 
LEVELS AMONGST SUBJECTS WITH ELEVATED 
TRANSAMINASES LEVELS
77%
23%
HIGH CHOLESTEROL 
NORMAL
CHOLESTEROL
 
Figure 4: NO OF SUBJECTS WITH NORMAL CHOLESTEROL AMONGST THE 43 WITH 
ELEVATED TRANSAMINASES. 
 
  
 
42 subjects out of the 43 subjects with elevated Transaminases, had 
either Fatty liver or Dyslipidemia.  Only one subject did not have 
neither Fatty liver nor Dyslipidemia. 
1
2%
42
98%
ABSENCE OF FATTY
LIVER AND
DYSLIPIDEMIA
PRESENCE OF FATTY
LIVER OR DYSLIPIDEMIA
 
Figure 5: NO OF SUBJECTS WITHOUT FATTY LIVER OR DYSLIPIDEMIA AMONG THE 43 
SUBJECTS WITH ELEVATED SR. TRANSAMINASES. 
 
These figures show that, the presence of elevated transaminases 
in the absence of Fatty Liver or Dyslipidemia is negligible ( only 1 
subject ). Sr. Transaminases are elevated only in the presence of Fatty 
liver or Dyslipidemia. Hence in our study, there is no direct correlation 
between BMI (obesity) and Sr. Transaminases levels. Sr. 
Transaminases are elevated only in the presence of Fatty liver or 
Dyslipidemia. 
 Descriptive statistical study for the correlation between BMI, and 
Sr. AST and Sr. ALT was done, both in the presence and absence of 
Fatty liver in ultrasonography. 
 
 There is not much correlation between BMI, and Sr. AST and Sr. 
ALT irrespective of whether fatty liver is present or not. The correlation 
values in both the cases varied between 0.1 and 0.3. 
 A “student’s t-test” was applied to show whether there is 
variation in Sr. AST and Sr. ALT values in the presence or absence of 
Fatty Liver. 
 
 Fatty liver N Mean StandardDeviation t 
Signifi
-cance 
PRESENT 39 56.4615 22.0381 4.267 **
AST 
ABSENT 21 32.3810 18.3806  
PRESENT 39 62.4615 26.0251 3.987 **
ALT 
ABSENT 21 37.0000 18.1052  
 
 The ‘t’ values show that there is a significant difference in the Sr. 
AST and Sr. ALT values at P < 0.01 level when Fatty Liver is 
present.The mean Sr. AST and Sr. ALT in the presence of Fatty Liver 
were 56.46 and 62.46 respectively, and the mean Sr. AST and Sr. ALT in 
the absence of Fatty liver were 32.38 and 37 respectively. The Sr. 
Transaminases are found to be elevated in subjects with Fatty Liver.  
 
 Many studies conducted in the past have compared the presence 
of Fatty liver and the levels of Serum Transaminases.  
 Daniel et al. in 1999 conducted a study in 81 asymptomatic 
patients with elevated liver enzymes, out of which 73 subjects had 
Nonalcoholic Fatty liver disease( NAFLD ) and 8 subjects had a normal 
Liver in Biopsy(73). 
 Sorbi et al. in 2000 conducted a study in 36 subjects with 
elevated Sr. Transaminases and found that 21 had NAFLD, 5 had 
PSC/PBC, 3 had autoimmune hepatitis, 3 had non-specific changes, 3 
had normal liver and 1 subject had Porfyria cutanea tarda in liver 
biopsy(74). 
 In a study of 354 subjects, conducted by Skelly et al. in 2001, 
235 subjects had NAFLD, 21 had a normal liver and rest of them had 
other liver diseases in Liver Biopsy(75). 
 In none of these studies BMI was directly correlated with Sr. 
Transaminases.  
In one large study conducted by Ruhl E, James E et al., in adult 
participants (5724) in the third U.S. National Health and Nutrition 
Examination Survey between 1988-1994, subjects  underwent 
anthropometric measures and phlebotomy after an overnight fast. 
Participants with excessive alcohol consumption, hepatitis B, hepatitis 
C, iron overload, or known diabetes were excluded. The results of this 
study concluded that, central adiposity, hyperleptinemia, and 
hyperinsulinemia were the major determinants of the association of 
overweight with elevated serum Sr. ALT activity and BMI is not directly 
correlated with the Sr. ALT levels(76). 
  
The results of these studies suggest that a liver biopsy is not 
mandatory in asymptomatic patients with an unexplained rise in Sr. 
AST or ALT, after a thorough non-invasive evaluation. Some of these 
persons were unnecessary 
subjected to a liver biopsy, because of the absence of liver disease or 
the lack of immediate therapeutical benefit of the biopsy findings. 
 The probability to diagnose NAFLD is high and lifestyle changes 
may be implemented without histological proof. Liver biopsy findings 
may sometimes point to a diagnosis which was overlooked at the time 
of the initial evaluation. Given the possible serious complications of 
liver biopsy (mortality 0.01%), it should not be performed to make up 
for a poor initial approach. The risks and benefits of a liver biopsy in 
this setting should be carefully considered, as it only seldom alters 
management. 
 Nonalcoholic Fatty Liver disease is a reversible condition, mainly 
by life-style and diet modifications, if unchecked may progress to 
steatohepatitis, fibrosis and cirrhosis. 
 All these subjects who had a high Total cholesterol value were 
advised to undergo a complete Fasting Lipid Profile which includes 
LDL( low density lipoprotein ), HDL ( high density lipoprotein ) and 
triglycerides. Patients with dyslipidemia were started on lipid lowering 
agents accordingly. Other subjects were given diet councelling and 
advised to execise physically. 
Why only certain obese people develop Nonalcoholic Fatty Liver 
Disease and others of the same BMI do not develop NAFLD, is not clear. 
Whether there is a genetic predisposition for the development, is not 
proven. There is an urgent need to conduct large population based 
studies in our Country from various ethnic and regional areas to 
understand the epidemiology of this increasingly common condition. 
Trends of the changes will provide health managers and policy makers 
the recipe for interventions. 
   
NOTE: In our study, which was conducted between August 2006 and 
August 2008, we have included obese women with BMI ≥30 
considering that, BMI ≥30 are obese according to the WHO standards. 
In November 2008, India has released its own BMI standards, 
specifically tailored for the Indian population. According to the Indian 
Revised BMI standards, BMI ≥23 are overweight and BMI ≥25 are 
Obese. Hence further epidemiological studies are required, considering 
the Indian Revised BMI standards and the evaluation of Nonalcoholic 
Fatty liver disease and Sr. Transaminases, including subjects falling 
under this new revised category. 
  
 
 
 
 
SUMMARY AND CONCLUSION ; 
 In our study, which was conducted in an Indian population with 
obese, Nonalcoholic subjects, 
• BMI ( Obesity ) is not directly correlated with Serum 
Transaminases. 
• Sr. Transaminases are elevated only in the presence of Fatty 
liver or           Dyslipidemia. 
• The mean Sr. AST and Sr. ALT values in subjects with Fatty 
liver were 56.46 and 62.46 respectively. Hence, there is a 
definite increase in  Serum Transaminase levels in the 
presence of Fatty liver. 
Encouragingly, Nonalcoholic Fatty Liver Disease is a reversible 
condition, and suitable lifestyle changes usually result in regression of 
Fatty , although drug therapy has not been fully validated. 
 Future directions require determination of the ‘critically elevated’ 
Serum Transaminases threshold value, development of drugs that 
would specifically and safely decrease Fatty Liver and subsequently 
reduction in Transaminases and conduction of interventional trials ( 
also including  obese subjects according to the new Indian revised BMI 
standards),  to study the influence of diet and life-style modifications 
on the levels of Serum Transaminases. 
   ********************************************* 
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